Targeting the CCL2-CCR2 axis interrupts the recruitment of monocytes to tumors, keeps monocytes in the bone marrow, reduces the number of M2-like TAMs at primary and metastatic sites, and increases CD8 T cells, finally inhibits tumor growth and invasion [68]. Here, CCL2 is linked to neoplasm.